腫瘤學(xué)-纖維肉瘤_第1頁
腫瘤學(xué)-纖維肉瘤_第2頁
腫瘤學(xué)-纖維肉瘤_第3頁
腫瘤學(xué)-纖維肉瘤_第4頁
腫瘤學(xué)-纖維肉瘤_第5頁
已閱讀5頁,還剩42頁未讀, 繼續(xù)免費閱讀

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認領(lǐng)

文檔簡介

SigMiddleagedFS,Dalmatian中年,母犬,History-theownersnoticedamassonthethoraxandimmedia ypresentedtotheRDVM.Physicalexam-massonthethorax(alwaysmeasure體檢-胸部有腫塊ProblemList問題列SCmassonthethorax胸部DDs鑒Diagnostic 計Fineneedleaspirate- PlanWheredothesetumorsmetastasizeLungsThoracicradiographs-noevidenceofWhatisthemainproblemwiththeseWhichtests erformLocalaggressivenesssoweshouldperformaCT!所以我們要做Inmanycases,despitenoevidenceofproblemsradiographs,whatweseeisthe“tipoftheSushi-BasedontheCT-thesurgerywasperformed,andcleanmarginswereobtained. ngfine,BAR.Theonlyabnormalityisthemassonthelateralthorax.DiagnosedattheRDVMwithaspindle a( ThoracicradiographswerewithinnormalAsthereisnoevidenceofmetastasis,wedecidedtoperformaCTpriortosurgery.由于無明顯轉(zhuǎn)移,我們決定在手術(shù)前進行CTShowClearly–inthiscase-surgeryisnotanoptionandwouldhavebeenamistake.Thedogisasymptomaticandcancontinuelivinguntilthetumoraffectshisqualityoflife.生活質(zhì)量IncidenceandRisk影響和風(fēng)險因 asaresolitaryintheolder dcat大 ashavebeenassociatedwithradiation,trauma,foreignbodies,andparasites Pathology病理Developfrommesenchymaltissues從間質(zhì)Donotincludetumorsofhematopoieticororigin不包括造血和淋巴系 的腫Oftenconsideredcollectivelyduetotheirsimilarityinclinicalbehaviorandsimilarityinhistologicfeatures.通ImportantCommon重要的共同特Tendtoappearpseudoencapsulatedsofttofirmtumorsbuthavedefinedhistologicmarginsorinfiltratethroughandalongfacialmargins-locallyinvasive趨于出現(xiàn)假包囊的由軟及硬的腫瘤,但是在組織學(xué)上沒有Localrecurrenceafterconservativesurgicalexcisionis局部復(fù)發(fā)在保守手術(shù)切除后常Tendtometastasizethroughhematogenousroutesinupto20%of高達20%病例會通過造血途徑RegionalLNmetsareunusualexceptsynovial)局部淋Histopathologicgradeispredictiveofmetastasis組織Resectedtumormarginspredictlocalrecurrence被切除腫瘤的邊緣預(yù)示PoorresponsetochemotherapyandradiationtherapyforbulkydiseaseDiagnosticTechniquesand FineneedleaspirateToruleoutlipomas,seromas,inflammation,abscess可排除脂肪 Problems-Poorcellularity-don’texfoliatewellresemblancebetweenreactivetissueandandmalignagnttumors.有反 FNAfromareasofnecrosis-falsenegative壞死組織細針DiagnosticTechniquesand Biopsy活Necessaryforadefinitivediagnosis!!確切 所必Plannedwell-tobeexcisedwithsurgerylater計劃好-后期的手術(shù)RadiographsXRegionalThoracicAdditionalimaging其他影UltrasoundMRICBCandChemistryPanel血規(guī)和生Therapy療Determinedbasedonspecies,location,clinicalstage,histologicMostsuccessful大多少成WidesurgicalexcisionbasedonCT手術(shù)切除廣泛(基于Ifthemarginsaredirty-eitheradditionalsurgeryand/or如果邊緣被污染-可附加手術(shù)和/Ifthehistologyrevealsahighgradetumorchemotherapy如組織學(xué)顯示為高度分化腫瘤-化Routinefollowup日常要追蹤觀Treatment(治療(放療Plavec.VCO.15dogswithSTSweretreatedwithpalliativeradiation15只患軟組織肉瘤的犬用緩和的放療來Cobalt3treatments0,7,14days3X8GyResponses1dog( a)-PRthensurgery1只犬(脂肪13dogsSDmedianTTP-263days(60-891+days)13只犬-平均存活263天1dogPD1只犬-PDMST平均存活時間332Treatment(治療(化療Selting.JAVMA.Examinedtheeffectofadjuvantdoxorubicinon eindogswithhighgrade(grade3)STSs檢查輔助使用阿霉素對高度分化腫瘤的犬的效39dogs39只OverallmedianDFI724days總共平均無病間期-724Mediansurvival856days平均存活856Nobenefitseenindogsthatreceivedchemotherapy接受化療無明Manypeople mendchemotherapy許多人仍建議化Prognosis預(yù)Prognosticindicators預(yù)后Histologicgradepredicativeofmetastasisandprognosis組織學(xué)Kuntzet13%ofgradeIdevelopedmetastasis,7%ofgradeIIand41%gradeIIIOverallmediansurvivalwithsurgeryalone1416days平均存活時間-1416Fordogswith>19mitoticfigures/10HPF-236daysvs1444fordogswith<10SizeSiteFavorablesuperficialextremities良好Unfavorabledeep,trunkinvasive,nearspinalcord軀干 的,脊髓附SurgicalmarginsPresentingComplaint現(xiàn)病Theownersnoticedamassbetweenhisshoulderblades主人發(fā)現(xiàn)兩肩間有一Signalment特征MCDSH9yearsold9History病Ownerfirstnoticedthemass2weeksago,itwasalmondsizedandhasbeengrowingHeisanindoorcat是只家養(yǎng)PhysicalExam(體檢(異常2.5*2.5cmmassattheinterscapularregion肩胛間有2.5*2.5厘米一個腫塊ThemassinSCandattachedtounderlyingtissue肩胛間腫塊附在下層組織ProblemList問題列SC,wellcicumscribed,attachedmassintheinterscapulararea2.5cmdiameter)SCPreliminaryDiagnostic初 計Fineneedleaspirate細針穿刺抽NondiagnosticAdditionaltestsweshould我們要追加其他測Additionaldiagnostic其 試Thoracicradiographs胸部XIncisionalbiopsyofthe腫塊的切開活Results-Thoracic結(jié)果-胸部Results結(jié)Thoracicrads-Around,approxima y4-5cmindiametersofttissuemassispresentdorsaltothemidthoracicvertebra.Thecardiovascularstructuresareunremarkable,asisthepulmonaryparenchyma.Results結(jié)Incisionalbiopsyofthemass- a腫Continuation-Diagnostic進一步 計Preanesthetictests麻醉前檢CBCChemistryPanelCTscanCT掃PlanCTScan計劃-CT掃CTScanCT掃Contrastenhancingleftdorsalthoracicsofttissuemasscompatiblewith a.Probableinvolvementofthelefttrapeziusmusclebellyandpossibleinvolvementoftheproximalaspectoftheleftscapula.Thenoncontrastenhancingportionwouldbeconsistentwithregionsofnecrosisorpoorvascularsupply. 影響左側(cè)斜方肌,也可能影響的左肩胛,這部分對比TherapeuticPlan治療計(PreOpradiationtherapy手術(shù)前放Surgery手Chemotherapy化DoxorubicinYuriwastreatedwithradiationtherapyFollowedbysurgeryand隨后進行手術(shù)和化Ayearlaterthereisnoevidenceofmetastasisorlocalrecurrence一年后無明顯轉(zhuǎn)移或局部復(fù)Statisticallylinkedtovaccination-FeLV,rabiesAlso-maybelongactingpenicillinandmethyl-prednisolone統(tǒng)計顯示,與免疫接種有Killedvaccineproducts;Subcutaneous滅 ,皮下注YoungeragegroupthanIncreasedRwithincreased#of增加狂 劑量,追加免IncreasedRwithrepeatvaccinationatsame相同部位,反復(fù)注射接種狂Usually2-10monthsaftervaccination通常免疫后維持2-10個1/10,000vaccinesgiven1/10,000免Pathology-Madewelletal as44只有纖維肉Grade1=25GradeII=48GradeIII271級25%,2級級Mitoticindex,differentiation,necrosis有 期,分化,壞MultinucleatedgiantcellsingradeIIandIIIonly只有2期和3期出多核巨細Mosthaveperitumorallymphocyticinflammation大多數(shù)有腫瘤樣巴細胞炎HighproportionofTcellsT細胞比例Increasedvasculardensityat 動脈管壁增Highcellularproliferation細胞增值Centrallylocatedmicroormacroabscesses位于中間有小或大的膿Grosspathology大體病理Histopathology組織Beforeradiotherapy放療 Afterradiotherapy放療PathogenesisAtsiteofinflammationinducedby在注 誘導(dǎo)的炎癥區(qū)Fibroblasticormyofibroblastic纖維細胞或MalignantRoleofadjuvants輔助藥物的NotlinkedtoFeLV,Clinical2-10monthsaftervaccination(48免疫后2-104cmdiameteratdiagnosis--rapid時直徑4locallyinvasive;infiltrativegrowth局 ,滲透性生長模regrowthafterinadequatesurgery10-25metastasize--lungandothersitesPreventionandDonotover不要過量免Usesingledose用單次劑量瓶Keepdetailedvaccine保持詳細的免疫記Standardizeandseparatevaccine標(biāo)準(zhǔn)化并分點注Exciseorbiopsyvaccine-sitereactionsthatpersist>3mo.,>2cmdiameter,orincreaseinsize1mo.after免疫后反應(yīng)持續(xù)超過個月后2厘米或接種后生長者,實施切除或?qū)γ庖邊^(qū)進行活檢Martanoetal-Surgeryaloneversussurgeryanddoxorubi

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

最新文檔

評論

0/150

提交評論